Recent 8-K filings for MIRM

• May 18, 2026, 4:06 PM ET debt materiality 0.80 neutral item 1.01item 2.03item 3.02item 8.01item 9.01 ◈ Debt Financings

  Mirum issues $690M zero-coupon convertible notes due 2032; exchanges $237M of 2029 notes

  Issued $690M aggregate principal of 0.00% Convertible Senior Notes due 2032, including $90M option exercise.

• May 6, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Mirum Q1 net sales $159.9M, raises FY guidance to $660-680M; volixibat & brelovitug meet primary endpoints

  Q1 2026 net product sales $159.9M, up 43% YoY; LIVMARLI $113.8M (+55%), Bile Acid Medicines $46.1M (+20%).

• May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01

  Mirum's volixibat meets primary endpoint in PSC Phase 2b VISTAS study with statistically significant itch reduction

  Volixibat showed 2.72 point improvement in pruritus vs 1.08 for placebo; placebo-adjusted difference 1.64 (p<0.0001).

• April 27, 2026, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Mirum's brelovitug meets Phase 2b primary endpoint in chronic HDV; 100% virologic response at 300 mg QW

  100% of patients on 300 mg QW and 75% on 900 mg Q4W achieved virologic response vs 0% control.

• April 8, 2026, 7:59 PM ET M&A materiality 0.70 neutral item 9.01

  Mirum completes acquisition of Bluejay Therapeutics with $268.5M PIPE; Bluejay reports 2025 net loss of $101.7M

  Concurrent PIPE raised $268.5M gross at $68.48/sh including pre-funded warrants.

• February 25, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Mirum Pharma 2025 sales $521M (+55% YoY); guides 2026 $630-650M; multiple pipeline readouts in 2026

  2025 net product sales $521.3M, up from $336.4M in 2024 (+55% YoY). LIVMARLI US sales $244.7M (+69% YoY).

• January 26, 2026, 6:59 PM ET M&A materiality 0.85 positive item 2.01item 7.01item 8.01item 9.01 ◈ M&A Transactions

  Mirum acquires Bluejay for $280.8M cash + stock; adds late-stage HDV therapy

  Upfront consideration $280.8M cash plus ~4.67M shares; holdback $25.8M plus ~0.52M shares; up to $200M milestones.

• January 12, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Mirum prelim 2025 sales ~$520M, above guidance; 2026 outlook $630-650M; acquiring Bluejay for HDV

  Preliminary 2025 net product sales ~$520M, exceeding upper end of guidance.

• December 19, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 7.01item 9.01

  Mirum Pharmaceuticals secures additional $68.5M PIPE from TCGX ahead of Bluejay acquisition

  1,000,000 shares at $68.48/share; ~$68.5M gross proceeds from TCGX.

• December 19, 2025, 6:59 PM ET litigation materiality 0.85 negative item 8.01

  Mirum Pharmaceuticals sues Sandoz, Annora, Zydus, Zenara over generic Livmarli ANDAs

  Received Paragraph IV notice letters from Sandoz, Annora Pharma, Zydus Lifesciences, and Zenara Pharma seeking generic Livmarli.

• December 8, 2025, 6:59 PM ET M&A materiality 1.00 positive item 1.01item 3.02item 7.01item 8.01item 9.01

  Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M

  Mirum pays $250M cash and up to 5.2M shares (≈$370M) at closing, plus up to $200M in milestone payments for Bluejay Therapeutics.

• November 17, 2025, 6:59 PM ET litigation materiality 0.75 negative item 8.01

  Mirum receives Sandoz Paragraph IV notice challenging Livmarli patents; plans to sue

  Sandoz filed ANDA seeking FDA approval for generic Livmarli (maralixibat).

• November 4, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Mirum Q3 revenue $133M, up 47% YoY; lifts FY guidance to $500-510M

  Q3 2025 total revenue $133.0M vs $90.4M in Q3 2024; LIVMARLI sales $92.2M (+56% YoY).

• August 6, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Mirum Q2 revenue $127.8M; raises FY 2025 guidance to $490-510M

  Q2 global net product sales $127.8M, up 64% YoY from $77.9M.

• May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Mirum Q1 revenue $111.6M; raises 2025 guidance to $435-450M

  Q1 2025 total revenue $111.6M vs $69.2M YoY, driven by LIVMARLI ($73.2M, +71%) and Bile Acid Medicines ($38.4M, +47%).

• February 26, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Mirum reports 2024 net product sales $336.4M; guides 2025 sales $420M-$435M

  2024 net product sales $336.4M, up from $178.9M in 2023; LIVMARLI sales $213.3M, Bile Acid Medicines $123.1M.

• January 13, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Mirum Pharma 2024 net sales ~$336M, above guidance; 2025 outlook $420-435M

  Preliminary unaudited FY2024 net product sales ~$336M, exceeding upper end of guidance range.

• November 12, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Mirum Q3 net product sales $90.3M (+89% YoY); raises FY 2024 guidance to $330-335M

  LIVMARLI net sales $59.1M; CHOLBAM/CHENODAL combined $31.2M.

• August 7, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Mirum Q2 net product sales $77.8M (+139% YoY); LIVMARLI sales $47.2M; positive volixibat interim data

  Q2 2024 global net product sales $77.8M, up 139% vs Q2 2023; full-year guidance reaffirmed at $310-320M.

• June 17, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01

  Mirum reports positive interim Ph2b data for volixibat in PBC and PSC

  VANTAGE PBC trial: volixibat achieved placebo-adjusted -2.32 point itch reduction (p=0.0026); 75% of patients had >50% drop in serum bile acids.

• May 31, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

  Mirum's LIVMARLI gets positive CHMP opinion for PFIC; EC decision in Q3 2024

  CHMP adopted positive opinion for LIVMARLI (maralixibat) to treat PFIC in patients aged 3 months and older.

• May 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Mirum Q1 revenue $69.2M, up 119% YoY; reaffirms FY guidance $310-320M

  Global product sales net $68.9M, up 137% vs Q1 2023; LIVMARLI net sales $42.8M (+47%).

• February 28, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Mirum reports 2023 net product sales of $178.9M (+142% YoY); guides 2024 sales $310-320M

  Full-year 2023 total revenue $186.4M, up 142% over 2022; LIVMARLI net sales $141.8M (+89% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.75 · Most common event earnings

18 positive 2 negative 5 neutral

source · MIRM on sec.gov